One-strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable.

ABSTRACT:

Background

Allergen immunotherapy (AIT) aims at modulating the immune response by administration of allergen preparations at regular intervals over several years (1). For subcutaneous AIT (SCIT), the treatment is initiated with a dose escalation phase followed by a maintenance dose administration. Over the last decade, there has been a trend towards shortening dose escalation regimens to increase patient adherence. This open-label, phase II trial aimed to investigate the safety and tolerability of a house dust mites (HDMs) SCIT product when used in a newly designed one-strength dose escalation scheme.

Method

Patients, aged 12-65, suffering from HDM-allergic rhinitis/rhinoconjunctivitis ± asthma were included. Patients were randomized to the one-strength (6 injections from th

SUBMITTER: Jutel M 

PROVIDER: S-EPMC11891436 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature